Reader View AI Reader View Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy? www.nasdaq.com · November 8, 2026 · 16:35 Paywall detected This article has a paywall The publisher blocks direct access to this article. Generate with AI Open link